SERPIN inhibitors for the treatment of prion and prion like diseases
New class of small molecules acting as SERPINA3 inhibitors, which are able to reduce PrPSc accumulation in prion-infected cell lines.
To date, despite numerous active efforts, there are no drugs available for the cure of the neurodegenerative diseases collectively referred as prion and prion-like disorders. Symptomatic treatment is the only available option, including the administration to patients of antipsychotics, such as quetiapine and clonazepam, to treat myoclonus, and of selective serotonin re-uptake inhibitors (SSRIs) to treat depression.
So far, there are no effective therapies for prion diseases. The proposed technology aims at developing novel molecules with improved efficacy on these devastating diseases.
Through this invention, we are presenting a new class of small molecules acting as SERPINA3 inhibitors, which are able to reduce PrPSc accumulation in prion-infected cell lines, thereby representing a new therapeutic treatment against prion and prion-like diseases.
Compounds for use in the therapeutic treatment of a prion or prion-like disease and to pharmaceutical compositions comprising these compounds.
The project is being developed at Scuola Internazionale Superiore di Studi Avanzati (SISSA). Thus far, the research team has characterized the system in vitro and partially in vivo. Further developments are expected in the coming months also depending on the identification of appropriate partnership.
Supplementary material and supporting data available upon request.
- EP EP Application n. 18170092 anhängig
Stichworteserpina3, serpina3n, protease inhibitors, prion-like disease